Human Microbiome Market Size - By Site (Digestive Tract, Lung), Application (Therapeutics, Diagnostics), Disease (Infectious Diseases, Gastrointestinal Diseases), Product (Drugs, Diagnostic Tests, Probiotics) & Global Forecast 2024-2032

Human Microbiome Market Size - By Site (Digestive Tract, Lung), Application (Therapeutics, Diagnostics), Disease (Infectious Diseases, Gastrointestinal Diseases), Product (Drugs, Diagnostic Tests, Probiotics) & Global Forecast 2024-2032

Human Microbiome Market Size

Human Microbiome Market size was valued at USD 824.4 million in 2023 and is expected to reach USD 6.47 billion by 2032, registering a CAGR of 25.7% till 2032. The growing prevalence of lifestyle-related diseases and the rising geriatric population has propelled the demand for innovative healthcare solutions.
 

As these factors contribute to an upsurge in chronic conditions, the significance of harnessing the potential of the human microbiome in disease management becomes increasingly apparent. Additionally, the growing demand for precision medicine, tailored to individual patient needs, has spotlighted the microbiome's pivotal role in personalizing treatment strategies.
 

The human microbiome refers to the collection of microorganisms, including bacteria, viruses, fungi, and other microbes, that inhabit various parts of the human body. These microorganisms live in and on the human body, forming complex ecosystems that play a crucial role in maintaining health and contributing to various physiological processes. Human microbiome industry is a rapidly growing field within the biotechnology and healthcare industries that focuses on understanding and harnessing the potential of the human microbiome.

COVID-19 Impact

The COVID-19 pandemic had a positive impact on the human microbiome market, fostering a renewed focus on health and immunity. The human microbiome has become an area of interest in recent times because of its association with several respiratory diseases and immunity. For instance, in April 2020, Persephone Biosciences Inc. started developing an immune-boosting microbiome therapeutic to help prevent and fight the novel coronavirus (SARS-CoV-2) and a potential stool-based diagnostic test designed to help predict which patients are at the highest risk for developing severe complications and mortality after suffering COVID-19.
 

Human Microbiome Market Trends

Increasing funding initiatives and government programs have emerged as potent drivers propelling the development of the industry. Recognizing the pivotal role that the human microbiome plays in maintaining overall health and its potential in revolutionizing disease management, governments and institutions worldwide are redirecting substantial investments toward research and development in this field. For instance, as per the National Institute of Health, in May 2022, the Federal Government of the U.S. incurred USD 864 million on research and development of the microbiome in 2021 and is expected to spend USD 903 million in 2022. Moreover, the establishment of supportive regulatory frameworks and incentives further augments this momentum, attracting both established players and new entrants to invest in microbiome-focused ventures.
 

Human Microbiome Market Restraint

Long regulatory pathways and high development costs present significant restraints for the industry. The complex nature of microbiome-based therapies requires thorough and meticulous regulatory scrutiny to ensure safety and efficacy. Navigating these regulatory processes often involves extended timelines and substantial financial investments. Additionally, the intricate interplay between the human microbiome and various health conditions necessitates comprehensive research and clinical trials, contributing to the high development costs.
 

Human Microbiome Market Analysis

By site, the human microbiome market is segmented into digestive tract, lung, reproductive cavity, skin, and other sites. The digestive tract segment held largest market share of 31.9% in 2022. With increasing awareness of the pivotal role that the gut microbiome plays in overall health, there has been a surge in research focused on understanding its impact on digestion and immunity. This heightened attention has driven the development of innovative probiotics, prebiotics, and other microbiome-targeted products that aim to balance and optimize the composition of the gut microbiota. Additionally, companies are investing in research, development, and commercialization of products targeting the digestive tract microbiome.
 

 

By application, the human microbiome market is segmented into therapeutics and diagnostics. The therapeutics segment held highest industry share of 65.2% in 2022. This rapid expansion can be attributed to the increasingly recognized influence of the human microbiome on overall health and disease. Development of several microbiome-based treatments that target a wide spectrum of medical conditions, ranging from gastrointestinal disorders to metabolic diseases and even certain immune-related ailments has spurred the demand for microbiome-based therapies. With a growing body of evidence supporting the efficacy of microbiome-based therapeutics.
 

Based on disease, the human microbiome market is segmented into infectious diseases, gastrointestinal diseases, endocrine & metabolic diseases, cancer, central nervous system disorder, and other diseases. The infectious diseases segment dominated the market in 2022 with a revenue of USD 278.2 million. High expansion can be attributed to a growing understanding of the intricate relationship between the human microbiome and various infectious diseases. The realization that the composition and balance of microorganisms residing within the human body can significantly influence susceptibility to infections has spurred intensive research and innovation. Technological advancements enabling in-depth microbial analysis, coupled with a shift towards personalized medicine, have further fuelled the momentum.
 

Based on products, the human microbiome market is segmented into drugs, probiotics, prebiotics, diagnostic tests, and other products. The drugs segment dominated the market with a market share of 40% and is poised to grow at a CAGR of 25.1% between 2023 – 2032. Expanding research into the intricate relationship between the human microbiome and various health conditions, coupled with breakthroughs in technology and development innovative therapeutic approaches has spurred the industry gains.. The development of microbiome-based drugs, designed to modulate the composition and activity of the microbiota for targeted medical interventions, has garnered significant attention from both academia and the pharmaceutical industry. As clinical trials continue to yield promising results, demonstrating the potential of microbiome-based drugs in addressing conditions ranging from gastrointestinal disorders, metabolic diseases, and neurological ailments.
 

North America dominated the human microbiome market in 2022, with a revenue of USD 261.2 million and is anticipated to grow at a CAGR of 24.9% by 2032 attributed to the advancements in microbiome research and growing emphasis on personalized medicine in the region. Also, the convergence of cutting-edge technologies, such as next-generation sequencing and bioinformatics, with a robust ecosystem of research institutions, biotech startups, and pharmaceutical giants, has paved the way for groundbreaking discoveries and the development of novel microbiome-based therapies. Moreover, significant investments and collaborative efforts among multidisciplinary experts.
 

Human Microbiome Market Share

Major market players operating in the human microbiome market include

• Seres Therapeutics
• Enterome
• Second Genome Inc.
• DuPont
• Synthetic Biologics, Inc.
• Synlogic
• Vedanta Biosciences, Inc.
• Metabiomics Corporation
• Microbiome Therapeutics LLC
• 4D pharma plc.
   

Human Microbiome Industry News

• In April 2023, Seres Therapeutics, Inc. and Nestlé Health Science announced the U.S. Food and Drug Administration (FDA) approval of VOWSTTM (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). This helped the company expand its product offerings.
   
• In April 2023, Vedanta Biosciences raised USD 106.5 million in financing to advance a pipeline of defined bacterial consortia therapies. The company aims to use the proceeds to support a pivotal Phase III trial of VE303 to prevent recurrent CDI.
   

The human microbiome market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Site

• Digestive tract
• Lung
• Reproductive cavity
• Skin
• Other sites

By Application

• Therapeutics
• Diagnostics

By Disease

• Infectious diseases
• Gastrointestinal diseases
• Endocrine & metabolic diseases
• Cancer
• Central nervous system disorder
• Other diseases

By Product

• Drugs
• Probiotics
• Prebiotics
• Diagnostic tests
• Other products

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA